SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
Abstract Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in reducing the risk of atrial fibrillation (AF). However, the results are controversial and the underlying metabolic mechanism remains unclear. Emerging evidence implied that SGLT2 inhibitors have extra benefic...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2023-10-01
|
| Col·lecció: | Cardiovascular Diabetology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12933-023-02019-8 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|